JAMA Network
About The Study: From 2020 to 2025, prior authorization for glucagon-like peptide-1 receptor agonists (GLP-1RAs) became near universal and out-of-pocket costs rose substantially in 2025, as plans increasingly required coinsurance. Although the rise in prior authorization may reflect efforts to curtail off-label GLP-1RA use, recent increases in out-of-pocket costs likely resulted from broader shifts to coinsurance affecting many high-cost drugs.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
